Senior Analytics Manager
RasaFull Time
Senior (5 to 8 years), Expert & Leadership (9+ years)
Advanced degree in Analytical Chemistry or related discipline with 10+ years of pharmaceutical industry experience in Analytical Development (AD) and Quality Control (QC). Demonstrated excellence in leadership and management of AD/QC activities in a small molecule drug development and commercial production environment. Experienced in leading AD/QC teams for commercial and development stages projects. Expertise in analytical activities supporting drug substance and pharmaceutical oral solids is required. Must have expert knowledge and hands-on experience with chromatographic methods.
Coordinate and oversee analytical development and commercial testing at contract testing laboratories for drug substance, drug product, and stability programs. Manage quality records, support regulatory filings, and provide technical leadership for operational procedures. Oversee analytical activities at CMO and CTL laboratories, including method development, validation, release, and stability. Perform data review, external auditing, exceptions management, and change control for GMP quality testing. Ensure contracted third-party testing complies with quality practices. Provide analytical development support for drug substance and formulation development. Support commercial manufacturing activities. Lead analytical method development, validation, and transfer activities. Lead the development and management of stage-appropriate stability programs. Lead the establishment and justification of specifications for drug substances and drug products. Author technical sections in regulatory submissions and respond to regulatory questions. Contribute to Annual Product Reviews. Support operational budgets, cost controls, and resource planning. Serve as an SME for analytical methodologies, specifications, stability, and reference standards during inspections and audits. Support inspection readiness activities.
Develops drugs for muscle function disorders
Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.